GP Update on Atrial Fibrillation (AF) Guidelines

Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia encountered in primary care and specialist practice, with prevalence rising in tandem with ageing populations and comorbidity, including hypertension, diabetes and obesity. Clinical management continues to develop, with recent guideline updates and trial data refining stroke prevention, rhythm control strategies and integrated care.

Key Points of Article:

• Stroke prevention remains a cornerstone with more and more evidence on antithrombotic strategies and personalised risk assessment.
• Rate vs rhythm control discussions are becoming more nuanced, with early rhythm control and catheter ablation expanding in appropriate patients.
• Technology is improving AF detection, particularly subclinical and paroxysmal presentations.
• Holistic care models, incorporating risk factor modification and coordinated services, are increasingly relevant in guideline frameworks.

Contemporary Guideline Foundations

Recent updates from major cardiology societies, including the 2024 European Society of Cardiology (ESC) Atrial Fibrillation Guidelines, outline a more structured, outcome‑oriented framework to AF management, emphasising comorbidity management, stroke prevention and tailored rate or rhythm strategies. These guidelines have been developed with multidisciplinary input, including cardiology and cardio‑thoracic surgery perspectives.¹

Key principles from this updated guidance include:

• An integrated pathway (often referenced as AF‑CARE) that prioritises Comorbidity and risk factor management, Avoidance of stroke and thromboembolism, Reducing symptoms with appropriate rate or rhythm control, and Evaluation and dynamic reassessment.²
• Flexible clinical decision‑making that accounts for changes in symptoms and risk profiles over time.¹

Risk Stratification and Stroke Prevention

Risk Scores

Stroke risk assessment remains central to AF care. The CHA₂DS₂‑VA score (a modification omitting sex category) has been highlighted in recent guideline discourse to simplify risk stratification while maintaining clinical relevance.

Oral anticoagulation continues to be recommended for patients above established thresholds, with direct oral anticoagulants (DOACs) preferred in many non‑valvular AF scenarios due to ease of use and predictable pharmacokinetics compared with vitamin K antagonists.

Developing Data on Antithrombotic Strategies

Data from major cardiology conferences suggest more nuanced considerations for antithrombotic therapy post‑intervention:

• The OCEAN trial presented at AHA 2025 evaluated the necessity of continued anticoagulation after successful catheter ablation, contributing to discussions around balancing stroke prevention with bleeding risk in selected patients.³
• Studies such as ADAPT AF‑DES and OPTIMA‑AF examine optimal antithrombotic regimens in patients undergoing percutaneous coronary intervention, informing clinical decisions in those with coexisting coronary disease.³
• The role of left atrial appendage closure (LAAC) versus medical therapy in high‑risk patients continues to be explored to guide stroke prevention strategies.³

This data supports a more personalised approach to stroke prevention across the AF spectrum.

Rate vs Rhythm Control: Shifting Perspectives

Historically framed as separate strategies, recent evidence and guidelines increasingly suggest:

• Early rhythm control may offer benefits of symptom reduction, potentially reducing hospitalisation and morbidity in selected patients.⁴
• Catheter ablation is gaining prominence not only for symptomatic relief but also as an early consideration in select patients, including those with heart failure where AF contributes to tachycardiomyopathy, though patient selection remains important.⁵

Clinical context, such as left ventricular function, symptom burden and patient preference, should guide rate and rhythm decisions.

Technology and Detection Advances

Recent clinical and technological trends continue to reshape AF detection and monitoring:

• Wearable and implantable monitoring devices, including long‑term ECG and photoplethysmography‑based wearables, are improving early detection and quantification of AF burden in asymptomatic or paroxysmal cases.⁶
• These technologies support more accurate diagnostics and personalised management plans, especially for patients with intermittent symptoms or cryptogenic stroke presentations.⁶

Routine pulse checks and targeted ECG screening for at‑risk populations including aged over 65, hypertension and prior stroke, remain best practice in primary care.

Risk Factor and Comorbidity Management

An increasingly recognised trend in contemporary AF care is a holistic approach that integrates lifestyle and risk factor modification:

• Address modifiable factors such as hypertension, diabetes, obstructive sleep apnoea, alcohol intake and obesity.
• Encourage structured cardiovascular risk reduction like blood pressure management, weight management and exercise as part of a comprehensive AF care plan.

This holistic prognosis aligns with guidelines that stress the importance of addressing underlying risk factors in AF management.⁷

Ablation Technology

Advances in rhythm control therapies include:

• Improved catheter ablation technology with refinements in technique and delivery.
• Pulsed‑field ablation and refined energy modalities aiming to target myocardial tissue with reduced impact on surrounding structures.⁶

Catheter ablation is increasingly considered in symptomatic, drug‑refractory AF and in patients with heart failure, though recurrence risk mandates ongoing evaluation and follow up are required.

Clinical Implications for GP Practice

Primary care clinicians have a significant part in:

• Early identification and diagnosis of AF through clinical assessment and ECG.
• Stroke risk stratification and anticoagulation decisions in collaboration with cardiology or specialist support where needed.
• Holistic risk factor management, including lifestyle advice and optimisation of comorbidities.
• Referral for specialist input when rhythm control strategies, complex anticoagulation decisions or procedural interventions are being considered.

In patients where atrial fibrillation coexists with structural heart disease or where surgical input may be required, refer to Dr Adrian Pick, Cardiothoracic Surgeon, for specialist assessment and planning coordination.

References:

1. European Society of Cardiology (n.d.). 2024 ESC Guidelines for the management of atrial fibrillation. Escardio. https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/atrial-fibrillation/
2. European Heart Journal, Volume 45, Issue 36, 21 September 2024, Pages 3314–3414, https://doi.org/10.1093/eurheartj/ehae176
3. New trials redefine Antithrombotic and stroke prevention strategies in AFib. (2025, November). American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2025/11/03/16/19/sat-315pm-afib-aha-2025
4. Mayo Clinic. (2025, November). Recent Updates in AF Guidelines [Video]. YouTube. https://www.youtube.com/watch?v=rdqbUcIKrY4
5. Dan, G. A., & Martinez-Rubio, A. (2025). The 2024 European Society of Cardiology Atrial Fibrillation Guidelines: A Moving Goalpost. European cardiology, 20, e01. https://doi.org/10.15420/ecr.2024.55
6. MA Changsheng, ZHAO Yize, WANG Wenyu.  Advances in the diagnosis and treatment of atrial fibrillation[J]. J Clin Cardiol, 2025, 41(3): 170-175. doi: 10.13201/j.issn.1001-1439.2025.03.002
7. Laura A. Campbell, Jessica P. Ammon, Rachana Kombathula, Naa’irah Muhammad, Christopher D. Jackson. (2025, May). New atrial fibrillation guideline: Modify risk, control rhythm, prevent progression. Cleveland Clinic Journal of Medicine. https://www.ccjm.org/content/92/5/291

This article is for information and educational purposes only and is intended for healthcare professionals. Clinicians should consider individual patient circumstances and refer to current guidelines. Patients should be encouraged to consult their GP or treating specialist.